1. Home
  2. CYTK vs USM Comparison

CYTK vs USM Comparison

Compare CYTK & USM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • USM
  • Stock Information
  • Founded
  • CYTK 1997
  • USM 1983
  • Country
  • CYTK United States
  • USM United States
  • Employees
  • CYTK N/A
  • USM N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • USM Telecommunications Equipment
  • Sector
  • CYTK Health Care
  • USM Telecommunications
  • Exchange
  • CYTK Nasdaq
  • USM Nasdaq
  • Market Cap
  • CYTK 5.6B
  • USM 5.8B
  • IPO Year
  • CYTK 2004
  • USM 1988
  • Fundamental
  • Price
  • CYTK $39.48
  • USM $68.65
  • Analyst Decision
  • CYTK Strong Buy
  • USM Buy
  • Analyst Count
  • CYTK 17
  • USM 3
  • Target Price
  • CYTK $81.63
  • USM $86.33
  • AVG Volume (30 Days)
  • CYTK 2.6M
  • USM 230.3K
  • Earning Date
  • CYTK 05-07-2025
  • USM 05-02-2025
  • Dividend Yield
  • CYTK N/A
  • USM N/A
  • EPS Growth
  • CYTK N/A
  • USM N/A
  • EPS
  • CYTK N/A
  • USM N/A
  • Revenue
  • CYTK $18,474,000.00
  • USM $3,770,000,000.00
  • Revenue This Year
  • CYTK $55.84
  • USM N/A
  • Revenue Next Year
  • CYTK $659.85
  • USM N/A
  • P/E Ratio
  • CYTK N/A
  • USM N/A
  • Revenue Growth
  • CYTK 145.34
  • USM N/A
  • 52 Week Low
  • CYTK $32.74
  • USM $33.75
  • 52 Week High
  • CYTK $68.76
  • USM $70.79
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 46.41
  • USM 56.79
  • Support Level
  • CYTK $37.79
  • USM $65.92
  • Resistance Level
  • CYTK $40.22
  • USM $68.44
  • Average True Range (ATR)
  • CYTK 3.16
  • USM 2.66
  • MACD
  • CYTK 0.25
  • USM 0.05
  • Stochastic Oscillator
  • CYTK 61.55
  • USM 78.66

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About USM United States Cellular Corporation

United States Cellular Corp is a regional wireless carrier that serves about 4.4 million customers spread across four major geographic clusters: the Midwest, mid-Atlantic, New England, and the Pacific Northwest. These service territories encompass a total population of about 32 million people. The vast majority of the markets the firm serves are rural or second/third-tier cities, with only the greater Milwaukee and Oklahoma City regions boasting populations greater than 1 million. us Cellular also owns a 5.5% stake in Verizon Wireless' Los Angeles operations and, unlike its wireless carrier peers, owns most of its towers. The firm has agreed to sell its wireless operations and most of its spectrum licenses in a series of transactions with T-Mobile, Verizon, and AT&T.

Share on Social Networks: